
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 8 / 2023
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 34,594 divided into 34,594 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs.
Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are available on the website: www.zealandpharma.com.
The exercise price was DKK 100.80 per share for 14,185 of the new shares and DKK 127.00 per share for 20,409 of the new shares. The total proceeds to Zealand from the capital increase amount to DKK 4,021,791.
The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma’s general meetings. Zealand Pharma has only one class of shares.
The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand Pharma will be nominal DKK 52,003,057 divided into 52,003,057 shares with a nominal value of DKK 1 each.
A full copy of the amended Articles of Association can be found at https://www.zealandpharma.com once registered with the Danish Business Authority.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.
Contact:
Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: ank@zealandpharma.com |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Calibre Announces the Publication of its 2022 Sustainability Report, Demonstrating Commitment to Transparency and Responsible Practices6.6.2023 12:00:55 CEST | Press release
VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) is pleased to announce the publication of its 2022 Sustainability Report (“the Report”). The Report outlines Calibre’s 2022 progress and achievements, provides guidance for the Company’s Environmental, Social and Governance (“ESG”) performance, and underscores Calibre’s unwavering commitment to transparency, accountability and responsible business practices. Calibre acknowledges that incorporating sustainability into its business strategy is essential to our long-term success. In 2022, the Company saw record production for the third consecutive year. Calibre’s increasing focus on sustainability practices and robust ESG performance ensures that such accomplishments are achieved in ways that are ethical, transparent, accountable, and respectful of the rights of others. Darren Hall, President and Chief Executive Officer, stated: “At Calibre, we recogniz
Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award6.6.2023 12:00:00 CEST | Press release
WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building. Dr. Monath was selected for the Gold Medal for his more than four decades of commitment to advancing knowledge of arboviruses and vaccine research and development (R&D) that contributed to the development of several innovative vaccines including those for Ebola Zaire, smallpox, dengue, Japanese encephalitis and West Nile. The Gold Medal, celebrating three decades of recognition, is Sabin’s highest scientific honor. It is given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Bill Foege, Anne
PRESS RELEASE: SSH launches OpenSSH support service for multi-platform SSH environments6.6.2023 12:00:00 CEST | Press release
Helsinki, Finland - June 6, 2023 - To resolve various customer support problems regarding OpenSSH implementations, SSH has launched a support service for OpenSSH. As a result, customers benefit from high-quality SSH support services also for the open-source variant of SSH software. OpenSSH will be supported on Windows and Red Hat Linux platforms. The SSH protocol is a secure network protocol used to establish encrypted and secure remote connections and transfer data between different systems. OpenSSH is an open-source implementation of the SSH protocol. It was initially released as a free version of SSH’s Tectia product. As an open-source product, OpenSSH is popular, especially as SSH client software. However, its usage in critical corporate environments has been partly limited due to a lack of high-quality support services or support from a single source for all SSH clients. Without proper support services, customers often invest in in-house OpenSSH expertise, resulting in increased o
Novo Nordisk A/S – Share repurchase programme6.6.2023 11:56:26 CEST | Press release
Bagsværd, Denmark, 6June 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 August 2023. Since the announcement 30 May of the programme, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement906,0001,042,810,01330 May 202382,7001,123.3192,897,99931 May 202385,0001,117.9295,023,0001 June 202385,0001,109.7994,332,2702 June 202390,0001,076.5596,889,206Accumulated under the
Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares6.6.2023 11:39:07 CEST | Press release
Company announcement no. 23 - 23 6 June 2023 Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), NTG Nordic Transport Group A/S (“NTG”), CVR no. 12546106, hereby announces receipt of the following notification from persons discharging managerial responsibilities in NTG, and persons closely associated with them, in NTG's shares and other financial instruments linked thereto: Eivind Drachmann Kolding (Chairman of the Board of Directors) Eivind Drachmann Kolding, Chairman of the Board of Directors of NTG, has on 2 June 2023 sold a total of 8,900 shares in NTG of nominally DKK 20 each at a price of DKK 439.63 per share. Reference is made to the attached notification. Additional information For additional information, please contact: Inves